This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exact Sciences (EXAS) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Exact Sciences' (EXAS) Q2 performance will likely reflect the benefit from continued adoption of the Oncotype DX breast test and robust Cologuard screening revenues.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) Key Surgical and Cantel Medical businesses make significant contributions to consumable revenues within the Healthcare arm in Q1.
Factors to Note Ahead of Humana (HUM) Q2 Earnings Release
by Zacks Equity Research
Humana's (HUM) second-quarter results are likely to reflect higher premiums from the Retail segment and overall membership growth, partly offset by elevated technology-linked investments.
Here's Why Alcon (ALC) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Alcon (ALC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Bio-Rad's (BIO) Clinical Diagnostics segment is expected to report growth in Q2, driven by its focus on laboratory workflow productivity, quality control, and new opportunities in molecular diagnostics.
Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) S.E.T. arm is expected to deliver strong results on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.
Lantheus (LNTH) to Report Q2 Results: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) Q2 performance is likely to gain from the continued uptake of PYLARIFY and DEFINITY.
Quest Diagnostics (DGX) Tops Q2 Earnings Estimates, Ups View
by Zacks Equity Research
Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raises its full-year 2022 guidance.
Abbott's (ABT) Q2 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
Abbott (ABT) reports better-than-expected results for Q2 2022, with robust contributions from the Established Pharmaceuticals, Diagnostics and Medical Device segments.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
LabCorp's (LH) Diagnostics base business organic volume is anticipated to have continued its rally in Q2, led by consistent growth in esoteric and routine procedures.
Molecular Diagnostics Sales to Drive Hologic (HOLX) Q3 Earnings
by Zacks Equity Research
Hologic's (HOLX) Q3 performance will likely benefit from the increased utilization of Panther instruments and contributions from its recent acquisitions.
What's in the Cards for HCA Healthcare's (HCA) Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter results are likely to benefit from better patient volumes. The results might partly suffer from escalating labor costs that might dampen bottom line growth.
Align Technology (ALGN) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Strong Invisalign adoption and continued growth in the iTero scanner installed base are likely to have driven Align Technology's (ALGN) Q2 performance.
Alcon's (ALC) Product Launches, Market Recovery Aid Growth
by Zacks Equity Research
Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.
Is a Beat Likely for Intuitive Surgical (ISRG) in Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
What's in Store for Thermo Fisher (TMO) in Q2 Earnings?
by Zacks Equity Research
The emergence of the new virus variants, through the months of Q2, is likely to have led to top-line contributions within Thermo Fisher's (TMO) Life-Science Solutions segment.
Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) Q3 results will likely gain from the continued uptake of its Panther instruments and an ongoing rebound in elective procedures.
What's in Store for Boston Scientific (BSX) in Q2 Earnings?
by Zacks Equity Research
Within the PI business of Boston Scientific (BSX), Q2 sales are expected to have been strong, banking on the strong performance of the drug-eluting franchise.
What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?
by Zacks Equity Research
Excluding COVID testing sales, Abbott's (ABT) worldwide Diagnostic sales are expected to have demonstrated strong growth in Q2 on the continuous rollout of Alinity.
Quest Diagnostics (DGX) to Report Q2 Earnings: What's In Store?
by Zacks Equity Research
Quest Diagnostics (DGX) second-quarter 2022 results will likely have gained from an ongoing rebound in the base business.
Here's Why Alcon (ALC) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Investors Should Retain Alcon (ALC) Stock For Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.
Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals
by Zacks Equity Research
The acquisition of EYSUVIS complements Alcon's (ALC) Systane family of eye drops offering, strengthening its treatment options for dry eye disease.
Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Grow
by Zacks Equity Research
Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.